Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs

Author(s): Farhad Jadidi-Niaragh, Abbas Mirshafiey

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 5 , Issue 1 , 2011

Become EABM
Become Reviewer


Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system and the most common cause of neurological disability in young adults, along with a considerable clinical and pathological heterogeneity. Since, current therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive phase of this disease, thus novel promising therapeutic strategies might open a light horizon in approaching to an efficient treatment in MS. In this review, we will discuss about relevant patents and novel designed immunosuppressive and anti-inflammatory oral drugs promising for treatment of multiple sclerosis.

Keywords: Multiple sclerosis, experimental autoimmune encephalomyelitis, fingolimod, FTY720, cladribine, triptolide, laquinimod, teriflunomide, fumaric acid, central nervous system, macrophages, EAE, immunization, RRMS, SPMS, PPMS, BBB, Fingolimod (FTY720), bradycardia, IFN-1a, FDA, Laquinimode, CLARITY, RA, SLE, Triperygium wilfordii, Alzheimer's disease, Parkinson disease, LLDT-8, mRNA, TGF-, (MMP)-1, (VCAM)-1, NF-AT, NF-B, NK, Th17 cells, PBMC, CD4+ T cells, DMF, MMF, NQO1, IL-10, AI, CD4+, BG00012, DEFINE, CONFIRM

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [66 - 80]
Pages: 15
DOI: 10.2174/187221311794474900

Article Metrics

PDF: 22